NCT04392310

Brief Summary

  1. 1.To assess overall survival of AML patient.
  2. 2.To measure rate of disease free survival.
  3. 3.rate of non relapse mortality.
  4. 4.rate of complete remission .
  5. 5.percentage of refractory disease.
  6. 6.percentage of relapsed disease.

Trial Health

35
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
50

participants targeted

Target at P25-P50 for all trials

Timeline
Completed

Started Jun 2020

Shorter than P25 for all trials

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

September 27, 2019

Completed
8 months until next milestone

First Posted

Study publicly available on registry

May 18, 2020

Completed
14 days until next milestone

Study Start

First participant enrolled

June 1, 2020

Completed
4 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

October 1, 2020

Completed
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

November 1, 2020

Completed
Last Updated

May 18, 2020

Status Verified

May 1, 2020

Enrollment Period

4 months

First QC Date

September 27, 2019

Last Update Submit

May 13, 2020

Conditions

Acute Myeloid Leukemia

Outcome Measures

Primary Outcomes (1)

  • Assessment of the overall survival of AML patients.

    Assessment of the overall survival of AML patients.

    One year

Eligibility Criteria

Age18 Years - 70 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Acute myeloid leukemia patients outcomes

You may qualify if:

  • AML patients, aged more than 18yrs and received chemotherapy (aggressive or palliative).

You may not qualify if:

  • patients less than 18years old.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Related Publications (1)

  • De Kouchkovsky I, Abdul-Hay M. 'Acute myeloid leukemia: a comprehensive review and 2016 update'. Blood Cancer J. 2016 Jul 1;6(7):e441. doi: 10.1038/bcj.2016.50.

    PMID: 27367478BACKGROUND

MeSH Terms

Conditions

Leukemia, Myeloid, Acute

Condition Hierarchy (Ancestors)

Leukemia, MyeloidLeukemiaNeoplasms by Histologic TypeNeoplasmsHematologic DiseasesHemic and Lymphatic Diseases

Study Design

Study Type
observational
Observational Model
OTHER
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Sohage Tema

Study Record Dates

First Submitted

September 27, 2019

First Posted

May 18, 2020

Study Start

June 1, 2020

Primary Completion

October 1, 2020

Study Completion

November 1, 2020

Last Updated

May 18, 2020

Record last verified: 2020-05